{"title":"非小细胞肺癌的靶向和免疫治疗最新进展","authors":"S. Ramalingham","doi":"10.17925/OHR.2017.13.02.77","DOIUrl":null,"url":null,"abstract":"Received: August 30, 2017 Published Online: November 17, 2017 Citation: Oncology & Hematology Review, 13(2):77–8 Corresponding Author: Suresh S Ramalingham, Winship at Emory University Hospital Midtown, 550 Peachtree Street, NE Atlanta, Georgia 30308, US. E: SSRAMAL@emory.edu I n recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances\",\"authors\":\"S. Ramalingham\",\"doi\":\"10.17925/OHR.2017.13.02.77\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Received: August 30, 2017 Published Online: November 17, 2017 Citation: Oncology & Hematology Review, 13(2):77–8 Corresponding Author: Suresh S Ramalingham, Winship at Emory University Hospital Midtown, 550 Peachtree Street, NE Atlanta, Georgia 30308, US. E: SSRAMAL@emory.edu I n recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.\",\"PeriodicalId\":44122,\"journal\":{\"name\":\"Oral History Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral History Review\",\"FirstCategoryId\":\"98\",\"ListUrlMain\":\"https://doi.org/10.17925/OHR.2017.13.02.77\",\"RegionNum\":1,\"RegionCategory\":\"历史学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HISTORY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral History Review","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.17925/OHR.2017.13.02.77","RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HISTORY","Score":null,"Total":0}
引用次数: 0
摘要
通讯作者:Suresh S Ramalingham, Winship, Emory University Hospital Midtown, 550 Peachtree Street, NE Atlanta, Georgia 30308, US。E: SSRAMAL@emory.edu近年来，非小细胞肺癌(NSCLC)的治疗前景发生了变化。针对特定基因改变的治疗方法的出现，如表皮生长因子(EGFR)突变，以及针对跨膜蛋白程序性死亡-1 (PD1)及其配体(PDL1)的免疫检查点抑制剂，增加了非小细胞肺癌患者的治疗选择。在一次专家访谈中，Suresh S Ramalingam讨论了靶向和免疫治疗的最新进展，并考虑了化疗在这种快速发展的治疗范式中的作用。
Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances
Received: August 30, 2017 Published Online: November 17, 2017 Citation: Oncology & Hematology Review, 13(2):77–8 Corresponding Author: Suresh S Ramalingham, Winship at Emory University Hospital Midtown, 550 Peachtree Street, NE Atlanta, Georgia 30308, US. E: SSRAMAL@emory.edu I n recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.
期刊介绍：
The Oral History Review, published by the Oral History Association, is the U.S. journal of record for the theory and practice of oral history and related fields. The journal’s primary mission is to explore the nature and significance of oral history and advance understanding of the field among scholars, educators, practitioners, and the general public. The Review publishes narrative and analytical articles and reviews, in print and multimedia formats, that present and use oral history in unique and significant ways and that contribute to the understanding of the nature of oral history and memory. It seeks previously unpublished works that demonstrate high-quality research and that offer new insight into oral history practice, methodology, theory, and pedagogy. Work published in the journal arises from many fields and disciplines, reflecting the interdisciplinary nature of oral history. While based in the U.S., the Review reflects the international scope of the field and encourages work from international authors and about international topics.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
